Thymoma

Adrenal Gland/Adrenocortical Basket Trials (Multiple Types) Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI) Bladder/Urothelial (GU) Bone Metastases Brain and Central Nervous System (CNS) Breast Cervical (GYN) Colon/Rectal/Anal (GI) Endocrine Cancers Endocrine Neoplasia Esophageal (GI) Gastric/Stomach (GI) Gastrointestinal (GI) (Multiple Types) General Solid Tumors (Multiple Types) GenitoUrinary (GU) (Multiple Types) GEP-NET (NEC) GI Stromal Tumor (GIST) Gynecologic (GYN) (Multiple Types) Head and Neck Cancers Hepatocellular/Liver (GI) Hodgkins Lymphoma Insulinoma Kidney/Renal Cell Carcinoma (GU) Leukemias Lung Lymphomas Melanoma/Skin Cancers Mesothelioma Multiple Myeloma NeuroBlastoma NeuroEndocrine (NEC) (Multiple Types) NeuroEndocrine Carcinoma (NEC) Osteosarcoma Ovarian Ovarian/Primary Peritoneal (GYN) Pancreatic (GI) Paraganglioma (NEC) Penile (GU) Pheochromocytoma (NEC) Prostate (GU) Salivary Gland Sarcoma Synovial Carcinoma Testicular (GU) Thymoma Thyroid Unknown Primary Cancers Uterine (GYN) Vulvar (GYN)

Last Updated: Wed Jul 17 2024

Study Status

Enrolling

On Hold

Not Enrolling

Unknown

NCT06086327

Chemokine Receptor CXCR4-targeting PET Imaging for Thymoma

Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.